skip to Main Content

Mosaic Therapeutics closes $28m series A funding and appoints Brian Gladsden as CEO

Mosaic Therapeutics, an oncology therapeutics company dedicated to resolving cancer’s complexity to power new treatments for patients, today announced the close of its $28 million series A funding round.

© 2025 AccentBio. All Rights Reserved.
Site designed by Grid24 a division of Grid24 Ltd.

Back To Top